

## CURRICULUM VITAE

**Thomas Poindexter Bersot, M.D., Ph.D.**

(b) (6)

### **Education**

1972–1974	Internship and first year residency in Medicine, University of California Hospitals, San Francisco
May 1972	M.D., Vanderbilt University
May 1972	Ph.D., Vanderbilt University
May 1966	A.B., University of Kentucky

### **Brief Chronology of Employment**

1996–present	Professor of Medicine, University of California, San Francisco (UCSF)
1990–present	Director, American Heart Association Lipid Disorders Training Center, University of California, San Francisco
1989–1996	Associate Clinical Professor of Medicine, UCSF
1979–present	Associate Investigator, Gladstone Institute of Cardiovascular Disease
1979–1989	Assistant Professor in Residence of Medicine, UCSF
1977–1979	Senior Investigator, National Heart, Lung, and Blood Institute, NIH
1976–1977	Chief Resident, National Heart, Lung, and Blood Institute, NIH
1974–1977	Clinical Associate, National Heart, Lung, and Blood Institute, NIH

### **Hospital Affiliations**

Director, Lipid Clinic, San Francisco General Hospital (SFGH)  
Attending Physician, SFGH  
Courtesy Staff Physician, UCSF Medical Center

### **Committees**

1990–1994	Executive Committee, SFGH
1991–1997	Chairman, Medical Records Committee, SFGH
1992–2002	Intern Selection Committee, Department of Medicine, School of Medicine, UCSF
1993–1997	Chairman, Forms Sub-Committee, Medical Records Committee, SFGH
1993–1997	Task Force on Improvement of Patient Referral Process to SFGH Clinics
1993–1997	Task Force on Improvement of Medical Record Availability
1994–1997	Marketing Committee of SFGH
1994–present	Committee on Human Research, UCSF
1997–2008	Clinical Affairs Committee, Council on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association

2002–2008	Chairman, Clinical Affairs Committee, Council on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association
2003–present	Vice-Chairman, Committee on Human Research, UCSF
2007–present	Member, Endocrinologic and Metabolic Drug Advisory Committee, United States Food and Drug Administration

#### **Professional Societies and Board Certification**

Council on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association  
National Lipid Association, Immediate Past President  
Pacific Lipid Association, Immediate Past President  
Diplomate, American Board of Internal Medicine  
Diplomate, American Board of Clinical Lipidology

#### **Honors and Other Special Scientific Recognition**

1972	Albert Weinstein Prize in Medicine
1972	Dean's Award for Student Research
1972	Amos Christie Award for Excellence in Pediatrics
1972	Merrill Award in Experimental Pathology
1967–1972	Vivian B. Allen Scholar

#### **Grant Awards**

1990–1992	W.M. Keck, Jr., Foundation
1989–1993	L.K. Whittier Foundation
1990–1996	American Heart Association Lipid Disorders Training Center
1997–present	American Heart Association Lipid Disorders Training Center funded by Merck and Co.

#### **Journal Review Responsibilities (*ad hoc*)**

*American Journal of Cardiology*  
*Arteriosclerosis, Thrombosis, and Vascular Biology*  
*Circulation*  
*Journal of Biological Chemistry*  
*Journal of Clinical Lipidology, Associate Editor*  
*Journal of Lipid Research*

#### **Research Interests**

- I. Plasma lipoprotein metabolism
  - Purification and analysis of the various apoprotein components of plasma lipoproteins.
  - Dietary regulation of plasma lipid metabolism.
- II. Cellular cholesterol metabolism
  - Control of cholesterol synthesis in cultured aortic smooth muscle cells and

fibroblasts.

- Mechanism of interaction of plasma lipoproteins with cells.

### III. Hyperlipoproteinemia

- Investigation of etiologic and therapeutic aspects of these disorders.

### IV. Prevention of coronary artery disease

- Investigation of eating behavior modification techniques to promote the reduction of coronary disease in the community.

## ABSTRACTS

1. Bersot TP, Brown WV, Levy RI, Windmueller HG, Fredrickson DS, and LeQuire VS (1970) Further characterization of rat plasma lipoprotein apoproteins. *Circulation* **42**: III-12.
2. Bersot TP, Brown WV, Levy RI, Windmueller HG, Fredrickson DS, and LeQuire VS (1970) Characterization of rat plasma lipoprotein apoproteins. *Fed. Proc.* **29**: 629.
3. Mahley RW, Bersot TP, Levy RI, Windmueller HG, and LeQuire VS (1970) Identity of lipoprotein apoproteins of plasma and liver Golgi apparatus in the rat. *Fed. Proc.* **29**: 629.
4. Mahley RW, Bersot TP, Brown MS, and Goldstein JL (1975) Regulation of sterol metabolism by a swine lipoprotein lacking apo-B. *Circulation* **52**: II-60.
5. Mahley RW, Weisgraber KH, Innerarity TL, and Bersot TP (1977) Identification of pro-arginine-rich apoprotein, a possible modulator of lipoprotein binding to cell surface receptors of human fibroblasts. *Circulation* **56**: III-57.
6. Bersot TP, Innerarity TL, Pitas RE, and Mahley RW (1977) High affinity binding to normal fibroblasts of a high density lipoprotein from abetalipoproteinemic and cholesterol-fed subjects. *Circulation* **56**: II-101.
7. Bersot TP and Mahley RW (1978) Phylogenetic analysis of high density lipoproteins and the alterations associated with cholesterol feeding in man and animals. *J. Am. Oil Chem. Soc.* **55**: 245A.
8. Bersot TP, Innerarity TL, and Mahley RW (1981) Stimulation of macrophage cholesteryl ester formation by  $\beta$ -VLDL from cholesterol-fed and hyperlipidemic subjects. *Clin. Res.* **29**: 536A.
9. Bersot TP, Adams LB, Snyder AH, and Mahley RW (1984) Combined family and school approach to reducing dietary cholesterol and saturated fat. (Presented at the 24th American Heart Association Conference on Cardiovascular Disease Epidemiology.) Cardiovascular Disease Epidemiology Newsletter (AHA), January 1984, p. 27.
10. Bersot TP, Innerarity TL, and Mahley RW (1984) Apo LP(a)-enriched chylomicrons induced by fat feeding bind to the macrophage-VLDL receptor. *Circulation* **70**: II-41.
11. Adams LB, Bersot TP, and Snyder AH (1984) Changes in eating behavior to reduce cholesterol are gender dependent. *Circulation* **70**: II-143.
12. Cheng CF, Bersot TP, and Bensadoun A (1984) Monoclonal antibodies specific for human hepatic triglyceride lipase. *Arteriosclerosis* **4**: 532a.
13. Bersot TP, Rall SC Jr, and Mahley RW (1985) Comparison of apolipoprotein[a] from postprandial d < 1.006 lipoproteins and lipoprotein[a]. In Proceedings of Poster Communications, 7th International Symposium on Atherosclerosis, (Fidge NH and Nestel PJ, eds.) Melbourne, October. International Atherosclerosis Society.
14. Bersot TP, Russell SJ, Pomernacki NK, Mahley RW, Weisgraber KH, and Fox CS (1992) A unique haplotype of the apolipoprotein B100 allele associated with familial defective apolipoprotein B100 observed during a study of the prevalence of this disorder. *Circulation* **86**: I-690.

## PUBLICATIONS

1. Bersot TP, Brown WV, Levy RI, Windmueller HG, Fredrickson DS, and LeQuire VS (1970) Further characterization of the apolipoproteins of rat plasma lipoproteins. *Biochemistry* **9**: 3427–3433.
2. Mahley RW, Bersot TP, LeQuire VS, Levy RI, Windmueller HG, and Brown WV (1970) Identity of very low density lipoprotein apoproteins of plasma and liver Golgi apparatus. *Science* **168**: 380–382.
3. Herbert PN, Windmueller HG, Bersot TP, and Shulman RS (1974) Characterization of the rat apolipoproteins. I. The low molecular weight proteins of rat plasma high density lipoproteins. *J. Biol. Chem.* **249**: 5718–5724.
4. Bersot TP, Mahley RW, Brown MS, and Goldstein JL (1976) Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts. *J. Biol. Chem.* **251**: 2395–2398.
5. Mahley RW, Weisgraber KH, Bersot TP, and Innerarity TL. (1978) Effects of cholesterol feeding on human and animal high density lipoproteins. In: *High Density Lipoproteins and Atherosclerosis* (Gotto AM, Jr., Miller NE, Oliver MF, eds.) Elsevier/North-Holland Biomedical Press, Amsterdam. pp. 149–176.
6. Innerarity TL, Mahley RW, Weisgraber KH, and Bersot TP (1978) Apoprotein (E—A-II) complex of human plasma lipoproteins. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E—A-II) complex. *J. Biol. Chem.* **253**: 6289–6295.
7. Mahley RW, Innerarity TL, Bersot TP, Lipson A, and Margolis S (1978) Alterations in human high-density lipoproteins, with or without increased plasma-cholesterol, induced by diets high in cholesterol. *Lancet* **2**: 807–809.
8. Weisgraber KH, Bersot TP, and Mahley RW (1978) Isolation and characterization of an apoprotein from the d<1.006 lipoproteins of human and canine lymph homologous with the rat A-IV apoprotein. *Biochem. Biophys. Res. Commun.* **85**: 287–292.
9. Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, and Sirtori CR (1980) A-I<sub>Milano</sub> apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. *J. Clin. Invest.* **66**: 901–907.
10. Bersot TP and Mahley RW. (1983) Lipoprotein receptors in lipid transport and atherogenesis. In: *Atherosclerosis: Mechanisms and Approaches to Therapy* (Miller NE, eds.) Raven Press, New York. pp. 143–152.
11. Bersot TP, Innerarity TL, Mahley RW, and Havel RJ (1983) Cholesteryl ester accumulation in mouse peritoneal macrophages induced by  $\beta$ -migrating very low density lipoproteins from patients with atypical dysbetalipoproteinemia. *J. Clin. Invest.* **72**: 1024–1033.
12. Bersot TP and Mahley RW. (1983) Mechanisms of atherogenesis in diet-induced and familial hyperlipidemia. In: *Dietary Fats and Health* (Perkins EG, Visek WJ, eds.) American Oil Chemists' Society, Champaign, IL. pp. 550–563.
13. Weisgraber KH, Rall SC, Jr., Bersot TP, Mahley RW, Franceschini G, and Sirtori CR (1983) Apolipoprotein A-I<sub>Milano</sub>. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. *J. Biol. Chem.* **258**:

- 2508–2513.
14. Havel RJ, Kotite L, Kane JP, Tun P, and Bersot T (1983) Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. *J. Clin. Invest.* **72**: 379–387.
  15. Rall SC, Jr., Weisgraber KH, Innerarity TL, Bersot TP, Mahley RW, and Blum CB (1983) Identification of a new structural variant of human apolipoprotein E, E2(Lys<sub>146</sub>→Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. *J. Clin. Invest.* **72**: 1288–1297.
  16. Innerarity TL, Bersot TP, Arnold KS, Weisgraber KH, Davis PA, Forte TM, and Mahley RW (1984) Receptor binding activity of high-density lipoproteins containing apoprotein E from abetalipoproteinemic and normal neonate plasma. *Metabolism* **33**: 186–195.
  17. Cheng C-F, Bensadoun A, Bersot T, Hsu JST, and Melford KH (1985) Purification and characterization of human lipoprotein lipase and hepatic triglyceride lipase. Reactivity with monoclonal antibodies to hepatic triglyceride lipase. *J. Biol. Chem.* **260**: 10720–10727.
  18. Bersot TP, Innerarity TL, Pitas RE, Rall SC, Jr., Weisgraber KH, and Mahley RW (1986) Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages. *J. Clin. Invest.* **77**: 622–630.
  19. Innerarity TL, Hui DY, Bersot TP, and Mahley RW (1986) Type III hyperlipoproteinemia: A focus on lipoprotein receptor-apolipoprotein E2 interactions. *Adv. Exp. Med. Biol.* **201**: 273–288.
  20. Bersot TP. (1986) Lipid metabolism. In: *Handbook of Clinical Endocrinology* (Fitzgerald PA, eds.) Jones Medical Publications, Greenbrae, CA. pp. 425–448.
  21. Rall SC, Jr., Newhouse YM, Clarke HRG, Weisgraber KH, McCarthy BJ, Mahley RW, and Bersot TP (1989) Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. *J. Clin. Invest.* **83**: 1095–1101.
  22. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, and McCarthy BJ (1990) Familial defective apolipoprotein B100: A mutation of apolipoprotein B that causes hypercholesterolemia. *J. Lipid Res.* **31**: 1337–1349.
  23. Bersot TP and Mahley RW. (1990) Overview of the atherogenicity of lipoproteins: Role of chylomicron remnants, very low density lipoprotein remnants, and low density lipoproteins. In: *Proceedings of the 14th International Congress of Nutrition* (Kim WY, Lee YC, Lee KY, Ju JS, Kim SH, eds.) The 14th ICN Organizing Committee, Ewha Womans University, Seoul, Korea. pp. 423–426.
  24. Mahley RW and Bersot TP. (1991) Lipid abnormalities: Mechanisms, clinical classifications, and management. In: *Cardiology. An Illustrated Text/Reference* (Chatterjee K, Cheitlin MD, Karliner J, Parmley WW, Rapaport E, Scheinman M, eds.) Vol. 2, J.B. Lippincott, Philadelphia. pp. 7.36–7.47.
  25. Frost PH and Bersot TP. (1992) Lipid metabolism. In: *Handbook of Clinical Endocrinology* (Fitzgerald PA, eds.) 2nd edition., Appleton & Lange, Norwalk, CT. pp. 582–616.
  26. Bersot TP, Russell SJ, Thatcher SR, Pomernacki NK, Mahley RW, Weisgraber KH,

- Innerarity TL, and Fox CS (1993) A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B-100 in a Chinese man discovered during a study of the prevalence of this disorder. *J. Lipid Res.* **34**: 1149–1154.
27. Mahley RW and Bersot TP. (1994) Lipid abnormalities: Mechanisms, clinical classifications, and management. In: *Cardiology* (Parmley WW, Chatterjee K, eds.) Vol. 2, Chapter 2, J. B. Lippincott, Philadelphia. pp. 1–20.
  28. Bersot TP. (1994) Endocrine disorders. In: *Cardiology and Co-existing Disease* (Rapaport E, eds.) Churchill Livingstone, New York. pp. 89–106.
  29. Bersot TP and Mahley RW. (1996) Clinical classifications of lipid abnormalities. In: *Atherosclerosis and Coronary Artery Disease* (Fuster V, Ross R, Topol EJ, eds.) Vol. 1, Lippincott-Raven, Philadelphia. pp. 163–169.
  30. Vega GL, Gao J, Bersot TP, Mahley RW, Verstraete R, Grundy SM, White A, and Cohen JC (1998) The –514 polymorphism in the hepatic lipase gene (*LIPC*) does not influence androgen-mediated stimulation of hepatic lipase activity. *J. Lipid Res.* **39**: 1520–1524.
  31. Bersot TP and Mahley RW (1998) A preliminary report on the sensitivity of plasma lipoproteins to low-dose simvastatin in nine Turkish men. *Arch. Turk. Soc. Cardiol.* **26**: 40–46.
  32. Mahley RW and Bersot TP (1999) Low levels of high-density lipoproteins in the Turkish population: A risk factor for coronary heart disease. *Arch. Turk. Soc. Cardiol.* **27**: 37–43.
  33. Bersot TP, Vega GL, Grundy SM, Palaoğlu KE, Atagündüz P, Özbayrakçı S, Gökdemir O, and Mahley RW (1999) Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population. *J. Lipid Res.* **40**: 432–438.
  34. Mahley RW, Pépin J, Palaoglu KE, Malloy MJ, Kane JP, and Bersot TP (2000) Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase: High density lipoprotein characterization and gender-specific effects of apolipoprotein E genotype. *J. Lipid Res.* **41**: 1290–1301.
  35. Mahley RW and Bersot TP. (2001) Drug therapy for hypercholesterolemia and dyslipidemia. In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics* (Hardman JG, Limbird LE, eds.) 10th edition., McGraw-Hill, New York. pp. 971–1002.
  36. Mahley RW, Arslan P, Pekcan G, Pépin GM, Ağaçdiken A, Karaagaoglu N, Rakıcıoğlu N, Nursal B, Dayanıklı P, Palaoglu KE, and Bersot TP (2001) Plasma lipids in Turkish children: Impact of puberty, socioeconomic status, and nutrition on plasma cholesterol and HDL. *J. Lipid Res.* **42**: 1996–2006.
  37. Mahley RW, Pépin GM, Bersot TP, Palaoglu KE, and Özer K (2002) Turkish Heart Study update: Plasma lipids and treatment guidelines for patients with low levels of high density lipoproteins (in Turkish). *Arch. Turk. Soc. Cardiol.* **30**: 93–103.
  38. Shohet RV, Vega GL, Bersot TP, Mahley RW, Grundy SM, Guerra R, and Cohen JC (2002) Sources of variability in genetic association studies: Insights from the analysis of hepatic lipase (*LIPC*). *Hum. Mutat.* **19**: 536–542.
  39. Mahley RW and Bersot TP (2001) Statins: Overwhelming evidence of efficacy and safety of these hypolipidemic drugs. *Turk. J. Endocrinol. Metab.* **5**: 131–140.

40. Mahley RW, Mahley LL, Bersot TP, Pépin GM, and Palaoglu KE (2002) The Turkish lipid problem: Low levels of high density lipoproteins. *Turk. J. Endocrinol. Metab.* **6**: 1–12.
41. Bersot TP, Palaoğlu KE, and Mahley RW (2002) Managing dyslipidemia in Turkey: Suggested guidelines for a population characterized by low levels of high density lipoprotein cholesterol. *Anadolu Kardiyol. Derg.* **4**: 315–322.
42. Bersot TP, Pépin GM, and Mahley RW (2003) Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. *Am. Heart J.* **146**: 1052–1060.
43. Raffai RL, McPherson R, Weisgraber KH, Innerarity TL, Rassart E, Bersot TP, and Milne RW (2003) Antibody phenotyping test for the human apolipoprotein E2 isoform. *Clin. Chem.* **49**: 1524–1526.
44. Bersot TP and Mahley RW. (2005) Clinical classifications of lipid abnormalities. In: *Atherothrombosis and Coronary Artery Disease* (Fuster V, Topol EJ, Nabel EG, eds.) 2nd edition., Lippincott Williams & Wilkins, Philadelphia. pp. 129–137.
45. Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Kesäniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Sharma SS, Nolan V, Middleton LT, Sundseth SS, Farrer LA, Mooser V, and Grundy SM (2005) Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). *Am. J. Cardiol.* **95**: 194–198.
46. Mahley RW, Can S, Özbayrakçı S, Bersot TP, Tanir S, Palaoğlu KE, and Pépin GM (2005) Modulation of high-density lipoproteins in a population in Istanbul, Turkey, with low levels of high-density lipoproteins. *Am. J. Cardiol.* **96**: 547–555.
47. Yu Y, Wyszynski DF, Waterworth DM, Wilton SD, Barter PJ, Kesäniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Ma Q, Sharma SS, Montgomery DS, Middleton LT, Sundseth SS, Mooser V, Grundy SM, and Farrer LA (2005) Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. *J. Lipid Res.* **46**: 2202–2213.
48. Mahley RW and Bersot TP. (2006) Drug therapy for hypercholesterolemia and dyslipidemia. In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics* (Brunton LL, Lazo JS, Parker KL, eds.) 11th edition., McGraw-Hill, New York. pp. 933–966.
49. Mahley RW, Pépin GM, Bersot TP, and Palaoğlu KE (2005) Low HDL-C in Turks: Genetic/lifestyle interactions modulate plasma levels. *Arch. Turk. Soc. Cardiol.* **33**: 381–391.
50. Bersot TP, Haffner S, Harris WS, Keelick KA, and Morris CM (2006) Hypertriglyceridemia: management of atherogenic dyslipidemia. *J. Fam. Pract.* **55**: S1–S8.
51. Barter P, McPherson YR, Song K, Kesäniemi AY, Mahley R, Waeber G, Bersot T, Mooser V, Waterworth D, and Grundy S. (2007) Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. *J. Clin. Endocrinol. Metab.* **92**: 1581–1589.



52. Can AS and Bersot TP. (2007) Analysis of agreement among definitions of metabolic syndrome in nondiabetic Turkish adults: a methodological study. BMC Public Health. 7: 353.
53. Can AS, Ozbayrakci S, Palaoglu KE, and Bersot TP (2009) Comparison between Turkish Cardiovascular Risk Platform and United States National cholesterol education Program Adult Treatment Panel III definitions of the metabolic syndrome in Turkish adults. J. Cardiometab. Syndr. 4: 26-32.
54. Ling H, Waterworth DM, Stirnadel HA, Pollin TI, Barter PJ, Kesäniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Cohen JC, Grundy SM, Mooser VE, and Mitchell BD. Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity (Silver Spring). 17:737-44.
55. Can AS, Bersot TP, and Gönen M. (2009) Anthropometric indices and their relationship with cardiometabolic risk factors in a sample of Turkish adults. Public Health Nutr. 12:538-46.